The immunogenicity results showed that after 28 days of sequential booster immunization with CanSino inhaled new crown vaccine, the neutralizing antibody levels against the original strain in the two dose groups were 18.4-26.4 times that of the inactivated homologous booster group, respectively. At the same time, the sequential strengthening of CanSino inhaled new crown vaccine also has a high level of cross-protection against the Delta mutant strain, and the level of neutralizing antibodies is 18.1-24 times that of the inactivated vaccine.
In addition, CanSino Biologics’ new crown vaccine for inhalation can also efficiently induce mucosal immunity. Within 28 days after the booster immunization, the IgA level of the new crown vaccine for sequential booster inhalation was significantly higher than that of the inactivated vaccine homologous booster.
The above research results confirm that CanSino’s inhaled COVID-19 vaccine only needs 1/5 of the intramuscular injection dosage form to generate neutralizing antibody levels higher than intramuscular injection, which can not only stimulate humoral and cellular immunity, but also efficiently induce mucosal immunity to achieve Triple comprehensive protection. At the same time, the vaccine has the unique advantages of being safe, effective, painless, convenient, and more accessible. It can induce higher levels of neutralizing antibodies than inactivated vaccine homologous boosting, which provides a powerful strategy for sequential boosting of the new crown vaccine. data support.
Post time: May-27-2022